[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100439898":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":41,"centralContacts":46,"locations":51,"responsibleParty":85,"collaborators":89,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":10,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":10,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":10,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Seattle Children's Hospital","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Youth with overweight\u002Fobesity and\u002For newly diagnosed T2D and elevated HbA1c",null,"All participants will undergo GFR (Iohexol Inj 300 MG\u002FML), EPRF (Aminohippurate Sodium Inj 20%), Dextran sieving (Dextran 40 Sodium Inj 0.9%), IVGTT for insulin sensitivity, in addition to BOLD and ASL Kidney MRI",[13,14,15],"Drug: Aminohippurate Sodium Inj 20%","Drug: Iohexol Inj 300 MG\u002FML","Drug: Dextran 40",{"label":17,"type":10,"description":11,"interventionNames":18},"Healthy normal-weight controls",[13,14,15],[20,29,35],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Aminohippurate Sodium Inj 20%","Diagnostic aid\u002Fagent used to measure effective renal plasma flow (ERPF)",[17,9],[26,27,28],"Sodium 4-amino hippurate (PAH) inj 20% 2g\u002F10mL","Para-aminohippurate","Aminohippuric acid",{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Iohexol Inj 300 MG\u002FML","Diagnostic aid\u002Fagent used to measure glomerular filtration rate (GFR)",[17,9],[34],"omnipaque 300",{"type":21,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Dextran 40","Diagnostic aid\u002Fagent used to measure glomerular size and selectivity",[17,9],[40],"Dextran Sieving",[42],{"name":43,"affiliation":44,"role":45},"Petter Bjornstad, MD","University of Washington - Medicine Diabetes Institute","PRINCIPAL_INVESTIGATOR",[47],{"name":43,"role":48,"phone":49,"phoneExt":10,"email":50},"CONTACT","(206) 616 3543","pettermb@uw.edu",[52,72],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Children's Hospital Colorado","RECRUITING","Aurora","Colorado","80045","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-104.83192,39.72943,{"lat":64,"lon":63},[67,71],{"name":68,"role":48,"phone":69,"phoneExt":10,"email":70},"Megan Kelsey, MD, MS","720-777-0991","Megan.Kelsey@childrenscolorado.org",{"name":68,"role":45,"phone":10,"phoneExt":10,"email":10},{"facility":5,"status":54,"city":73,"state":74,"zip":75,"country":58,"countryCode":59,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Seattle","Washington","98102",{"type":61,"coordinates":77},[78,79],-122.33207,47.60621,{"lat":79,"lon":78},[82,84],{"name":83,"role":48,"phone":49,"phoneExt":10,"email":50},"Petter M Bjornstad, MD",{"name":83,"role":45,"phone":10,"phoneExt":10,"email":10},{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Petter Bjornstad","Assistant Professor",[90,93,94],{"name":91,"class":92},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",{"name":5,"class":6},{"name":95,"class":6},"University of Colorado, Denver","100439898","puberty-diabetes-and-the-kidneys-when-eustress-becomes-distress-panther-study-100439898",false,"NCT05008276","Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)","PANTHER Study: Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress","Inclusion Criteria:\n\n* HbA1c ≥6.0% for untreated high-risk group\n* BMI ≥ 85th %ile for high-risk group\n* Normal HbA1c ≤5.6% for control group\n* Type 1 diabetes (T1D) Antibody negative\n\nExclusion Criteria:\n\n* History of Chronic kidney disease (CKD) or acute kidney injury (AKI)\n* Metabolic disorder prohibiting safe fasting\n* Iodine or penicillin allergy\n* Pregnancy\n* Thrombophilia\n* MRI contraindications\n* Hormone therapy",true,"ALL","8 Years","14 Years",{"count":108,"type":109},100,"ESTIMATED","OBSERVATIONAL","Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.",[113,114,115,116,117,118],"Type 2 Diabetes Mellitus","Diabetic Kidney Disease","Adolescent Obesity","Pre Diabetes","Kidney Hypoxia","Puberty","2025-03-20",{"date":121,"type":122},"2025-03-24","ACTUAL",{"date":124,"type":122},"2021-09-27",{"date":126,"type":109},"2027-12-01",{"name":87,"class":6},2]